Yr Athro Paul Brennan

2021

• Brennan, P. 2021. Data visualization with the programming language R. Biochemist 43(5), pp. 8–14. (10.1042/bio_2021_174)
• Alsagaby, S. A. et al. 2021. Proteomics-based identification of cancer-associated proteins in chronic lymphocytic leukaemia. Electronic Journal of Biotechnology 52, pp. 1-12. (10.1016/j.ejbt.2021.04.006)

2020

• Ipseiz, N., Czubala, M. A., Bart, V. M., Davies, L. C., Jenkins, R. H., Brennan, P. and Taylor, P. R. 2020. Effective in vivo gene modification in mouse tissue-resident peritoneal macrophages by intraperitoneal delivery of lentiviral vectors. Molecular Therapy - Methods and Clinical Development 16, pp. 21-31. (10.1016/j.omtm.2019.10.004)

2018

• Brennan, P. 2018. drawProteins: a Bioconductor/R package for reproducible and programmatic generation of protein schematics. F1000Research 7, article number: 1105. (10.12688/f1000research.14541.1)
• Brennan, P. 2018. drawProteins, package to draw protein schematics from Uniprot API output. Bioconductor.

2016

• Alsagaby, S. A., Brennan, P. and Pepper, C. 2016. Key molecular drivers of chronic lymphocytic leukemia. Clinical Lymphoma, Myeloma and Leukemia 16(11), pp. 593-606. (10.1016/j.clml.2016.08.008)
• Welton, J. . L. et al. 2016. Proteomics analysis of vesicles isolated from plasma and urine of prostate cancer patients using a multiplex, aptamer-based protein array. Journal of Extracellular Vesicles 5, article number: 31209. (10.3402/jev.v5.31209)

2014

• Walsby, E. et al. 2014. Development and characterization of a physiologically relevant model of lymphocyte migration in chronic lymphocytic leukemia. Blood 123(23), pp. 3607-3617. (10.1182/blood-2013-12-544569)
• Alsagaby, S. A. et al. 2014. Proteomics-based strategies to identify proteins relevant to chronic lymphocytic leukemia. Journal of Proteome Research 13(11), pp. 5051-5062. (10.1021/pr5002803)

2013

• Wong, R. F., Pepper, C. J., Brennan, P., Nagorsen, D., Man, S. T. and Fegan, C. D. 2013. Blinatumomab induces autologous T cell killing of chronic lymphocytic leukemia cells. Haematologica 98(12), pp. 1930-1938. (10.3324/haematol.2012.082248)

2012

• Hoogendoorn, B. et al. 2012. Gene and protein responses of human lung tissue explants exposed to ambient particulate matter of different sizes. Inhalation Toxicology 24(14), pp. 966-975. (10.3109/08958378.2012.742600)
• Hamilton, E. et al. 2012. Mimicking the tumour microenvironment: three different co-culture systems induce a similar phenotype but distinct proliferative signals in primary chronic lymphocytic leukaemia cells. British Journal of Haematology 158(5), pp. 589-599. (10.1111/j.1365-2141.2012.09191.x)
• Masgras, I. et al. 2012. Reactive oxygen species and mitochondrial sensitivity to oxidative stress determine induction of cancer cell death by p21. Journal of Biological Chemistry 287(13), pp. 9845-9854. (10.1074/jbc.M111.250357)
• Pepper, C. J. et al. 2012. Defining the prognosis of early stage chronic lymphocytic leukaemia patients. British Journal of Haematology 156(4), pp. 499-507. (10.1111/j.1365-2141.2011.08974.x)

2011

• Watkins, C. L., Sayers, E. J., Allender, C. J., Barrow, D. A., Fegan, C. D., Brennan, P. and Jones, A. T. 2011. Co-operative membrane disruption between cell-penetrating peptide and cargo: implications for the therapeutic use of the Bcl-2 converter peptide D-NuBCP-9-r8. Molecular Therapy 19(12), pp. 2124-2132. (10.1038/mt.2011.175)
• Sexton, K. J., Balharry, D. C., Brennan, P., McLaren, J. E., Brewis, I. A. and Berube, K. A. 2011. Proteomic profiling of human respiratory epithelia by iTRAQ reveals biomarkers of exposure and harm by tobacco smoke components. Biomarkers 16(7), pp. 567-576. (10.3109/1354750X.2011.608855)
• Pepper, C. J. et al. 2011. Two novel aspirin analogues show selective cytotoxicity in primary chronic lymphocytic leukaemia cells that is associated with dual inhibition of Rel A and COX-2. Cell Proliferation 44(4), pp. 380-390. (10.1111/j.1365-2184.2011.00760.x)

2010

• Welton, J. L. et al. 2010. Proteomics analysis of bladder cancer exosomes. Molecular & Cellular Proteomics 9(6), pp. 1324-1338. (10.1074/mcp.M000063-MCP201)
• Pearce, L. et al. 2010. Genetic modification of primary chronic lymphocytic leukemia cells with a lentivirus expressing CD38. Haematologica 95(3), pp. 514-517. (10.3324/haematol.2009.014381)
• Tediose, T., Kolev, M. V., Baalasubramanian, S., Brennan, P., Morgan, B. P. and Donev, R. M. 2010. Interplay between REST and nucleolin transcription factors: a key mechanism in the overexpression of genes upon increased phosphorylation. Nucleic Acids Research 38(9), pp. 2799-2812. (10.1093/nar/gkq013)
• Vaisitti, T. et al. 2010. CD38 increases CXCL12-mediated signals and homing of chronic lymphocytic leukemia cells. Leukemia 24(5), pp. 958-969. (10.1038/leu.2010.36)
• Alnagar, F., Brennan, P. and Brewis, I. A. 2010. Bicarbonate-dependent serine/threonine protein dephosphorylation in capacitating boar spermatozoa. Journal of Andrology 31(4), pp. 393-405. (10.2164/jandrol.109.008383)
• Brewis, I. and Brennan, P. 2010. Proteomics technologies for the global identification and quantification of proteins. In: Donev, R. ed. Advances in Protein Chemistry and Structural Biology., Vol. 80. Elsevier, pp. 1-44., (10.1016/B978-0-12-381264-3.00001-1)

2009

• Watkins, C. L., Brennan, P., Fegan, C. D., Takayama, K., Nakase, I., Futaki, S. and Jones, A. T. 2009. Cellular uptake, distribution and cytotoxicity of the hydrophobic cell penetrating peptide sequence PFVYLI linked to the proapoptotic domain peptide PAD. Journal of Controlled Release 140(3), pp. 237-244. (10.1016/j.jconrel.2009.04.028)
• Pepper, C. J., Hewamana, S., Brennan, P. and Fegan, C. D. 2009. NF-κB as a prognostic marker and therapeutic target in chronic lymphocytic leukemia. Future Oncology 5(7), pp. 1027-1037. (10.2217/fon.09.72)
• McLaren, J. E., Zuo, J., Grimstead, J. W., Poghosyan, Z., Bell, A. I., Rowe, M. and Brennan, P. 2009. STAT1 contributes to the maintenance of the latency III viral programme observed in Epstein-Barr virus-transformed B cells and their recognition by CD8+ T cells. Journal of General Virology 90(9), pp. 2239-2250. (10.1099/vir.0.011627-0)
• Brennan, P. et al. 2009. Quantitative nuclear proteomics reveals new phenotypes altered in lymphoblastoid cells. Proteomics - Clinical Applications 3(3), pp. 359-369. (10.1002/prca.200800137)
• Hewamana, S. et al. 2009. Rel A is an independent biomarker of clinical outcome in chronic lymphocytic leukemia. Journal of Clinical Oncology 27(5), pp. 763-769. (10.1200/JCO.2008.19.1114)
• Raby, A. et al. 2009. Soluble TLR2 reduces inflammation without compromising bacterial clearance by disrupting TLR2 triggering. The Journal of Immunology 183(1), pp. 506-517. (10.4049/jimmunol.0802909)

2008

• Hewamana, S. et al. 2008. The novel nuclear factor- B inhibitor LC-1 is equipotent in poor prognostic subsets of chronic lymphocytic leukemia and shows strong synergy with fludarabine. Clinical Cancer Research 14(24), pp. 8102-8111. (10.1158/1078-0432.CCR-08-1673)
• Pepper, C. J. et al. 2008. Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. Blood 112(9), pp. 3807-3817. (10.1182/blood-2008-05-157131)
• Hewamana, S. et al. 2008. The NF-κB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target. Blood 111(9), pp. 4681-4689. (10.1182/blood-2007-11-125278)
• Chong, L. K., Aicheler, R., Llewellyn-Lacey, S., Tomasec, P., Brennan, P. and Wang, E. C. Y. 2008. Proliferation and interleukin 5 production by CD8hiCD57+ T cells. European Journal of Immunology 38(4), pp. 995-1000. (10.1002/eji.200737687)
• Brennan, P., Donev, R. M. and Hewamana, S. 2008. Targeting transcription factors for therapeutic benefit. Molecular Biosystems 4(9), pp. 909-919. (10.1039/b801920g)
• Brennan, P. 2008. Duplication: most cases on database are innocent [Letter]. Nature 452(7183), pp. 29. (10.1038/452029d)

2007

• McLaren, J. E., Rowe, M. and Brennan, P. 2007. Epstein-Barr virus induces a distinct form of DNA-bound STAT1 compared with that found in interferon-stimulated B lymphocytes. Journal of General Virology 88(7), pp. 1876-1886. (10.1099/vir.0.82741-0)
• Pepper, C. J. et al. 2007. Highly purified CD38+ and CD38- sub-clones derived from the same chronic lymphocytic leukemia patient have distinct gene expression signatures despite their monoclonal origin. Leukemia 21(4), pp. 687-696. (10.1038/sj.leu.2404587)

2006

• Shore, A. M., White, P. C., Hui, R. C., Essafi, A., Lam, E. W., Rowe, M. and Brennan, P. 2006. Epstein-Barr virus represses the FoxO1 transcription factor through latent membrane protein 1 and latent membrane protein 2A. Journal of Virology 80(22), pp. 11191-11199. (10.1128/JVI.00983-06)
• White, P. C., Shore, A. M., Clement, M., McLaren, J. E., Soeiro, I., Lam, E. W. and Brennan, P. 2006. Regulation of cyclin D2 and the cyclin D2 promoter by protein kinase A and CREB in lymphocytes. Oncogene 25(15), pp. 2170-2180. (10.1038/sj.onc.1209255)
• Omidvar, N., Wang, E. C. Y., Brennan, P., Longhi, M. P., Smith, R. A. G. and Morgan, B. P. 2006. Expression of glycosylphosphatidylinositol-anchored CD59 on target cells enhances human NK cell-mediated cytotoxicity. Journal of immunology 176(5), pp. 2915-2923.
• Omidvar, N., Wang, E. C. Y., Brennan, P., Longhi, M. P., Smith, R. A. G. and Morgan, B. P. 2006. Expression of glycosylphosphatidylinositol-anchored CD59 on target cells enhances human NK cell-mediated cytotoxicity. The Journal of Immunology 176(5), pp. 2915-2923. (10.4049/jimmunol.176.5.2915)
• Pepper, C. J. et al. 2006. CD38+ chronic lymphocytic leukaemia cells co-express high levels of ZAP-70 and are functionally distinct from their CD38− counter-parts. Leukemia 20(4), pp. 743-744. (10.1038/sj.leu.2404133)

2005

• Siebert, S., Fielding, C. A., Williams, B. D. and Brennan, P. 2005. Mutation of the extracellular domain of tumour necrosis factor receptor 1 causes reduced NF‐κB activation due to decreased surface expression. FEBS Letters 579(23), pp. 5193-5198. (10.1016/j.febslet.2005.08.037)
• Siebert, S., Williams, B. D. and Brennan, P. 2005. Reply [Letter]. Arthritis & Rheumatism 52(9), pp. 2952-2953. (10.1002/art.21369)
• Richardson, C. J., Brennan, P., Powell, M. B., Prince, S. N., Chen, Y., Spiller, O. B. and Rowe, M. 2005. Susceptibility of B lymphocytes to adenovirus type 5 infection is dependent upon both coxsackie-adenovirus receptor and αvβ5 integrin expression. Journal of General Virology 86(6), pp. 1669-1679. (10.1099/vir.0.80806-0)
• Siebert, S., Amos, N., Fielding, C. A., Wang, E. C. Y., Aksentijevich, I., Williams, B. D. and Brennan, P. 2005. Reduced tumor necrosis factor signaling in primary human fibroblasts containing a tumor necrosis factor receptor superfamily 1A mutant. Arthritis & Rheumatism 52(4), pp. 1287-1282. (10.1002/art.20955)
• Breslin, E. M., White, P., Shore, A. M., Clement, M. and Brennan, P. 2005. LY294002 and rapamycin co-operate to inhibit T-cell proliferation. British Journal of Pharmacology 144(6), pp. 791-800. (10.1038/sj.bjp.0706061)

2004

• Sathish, J. G. et al. 2004. CD22 is a functional ligand for SH2 domain-containing protein-tyrosine phosphatase-1 in primary T cells. Journal of Biological Chemistry 279(46), pp. 47783-47791. (10.1074/jbc.M402354200)
• Fielding, C. A., Siebert, S., Rowe, M. and Brennan, P. 2004. Analysis of human tumour necrosis factor receptor 1 dominant-negative mutants reveals a major region controlling cell surface expression. FEBS Letters 570(1-3), pp. 138-142. (10.1016/j.febslet.2004.06.035)
• Moutaftsi, M., Brennan, P., Spector, S. A. and Tabi, Z. 2004. Impaired lymphoid chemokine-mediated migration due to a block on the chemokine receptor switch in human cytomegalovirus-infected dendritic cells. Journal of Virology 78(6), pp. 3046-3054. (10.1128/JVI.78.6.3046-3054.2004)

2003

• Burchill, M. A. et al. 2003. Distinct effects of STAT5 activation on CD4(+) and CD8(+) T cell homeostasis: Development of CD4(+)CD25(+) regulatory T cells versus CD8(+) memory T cells. The Journal of Immunology 171(11), pp. 5853-5864.
• Richardson, C. J., Fielding, C., Rowe, M. and Brennan, P. 2003. Epstein-Barr virus regulates STAT1 through latent membrane protein 1. Journal of Virology 77(7), pp. 4439-4443. (10.1128/JVI.77.7.4439-4443.2003)
• Ohtani, N. et al. 2003. Epstein-Barr virus LMP1 blocks p16INK4a-RB pathway by promoting nuclear export of E2F4/5. Journal of cell biology 162(2), pp. 173. (10.1083/jcb.200302085)
• Prince, S., Keating, S., Fielding, C., Brennan, P., Floettmann, E. and Rowe, M. 2003. Latent membrane protein 1 inhibits Epstein-Barr virus lytic cycle induction and progress via different mechanisms. Journal of Virology 77(8), pp. 5000-5007. (10.1128/JVI.77.8.5000-5007.2003)

2002

• Brennan, P., Mehl, A. M., Jones, M. and Rowe, M. 2002. Phosphatidylinositol 3-kinase is essential for the proliferation of lymphoblastoid cells. Oncogene 21(8), pp. 1263-1271. (10.1038/sj.onc.1205182)
• Saitoh, M., Pullen, N., Brennan, P., Cantrell, D., Dennis, P. B. and Thomas, G. 2002. Regulation of an activated S6 kinase 1 variant reveals a novel mammalian target of rapamycin phosphorylation site. Journal of Biological Chemistry 277(22), pp. 20104-20112. (10.1074/jbc.M201745200)

2001

• Mehl, A. M., Jones, M., Rowe, M. and Brennan, P. 2001. Characterization of a CD40-dominant inhibitory receptor mutant. The Journal of Immunology 167(11), pp. 6388-6393.
• Sathish, J. G. et al. 2001. Requirement for CD28 co-stimulation is lower in SHP-1-deficient T cells. European Journal of Immunology 31(12), pp. 3649-3658. (10.1002/1521-4141(200112)31:12<3649::AID-IMMU3649>3.0.CO;2-8)
• Fielding, C. A., Sandvej, K., Mehl, A. M., Brennan, P., Jones, M. and Rowe, M. 2001. Epstein-Barr virus LMP-1 natural sequence variants differ in their potential to activate cellular signaling pathways. Journal of Virology 75(19), pp. 9129-9141. (10.1128/JVI.75.19.9129-9141.2001)
• Brennan, P. and Athie-Morales, V. 2001. Analysis of interleukin-2 signaling using affinity precipitations and polyacrylamide gel electrophoresis. In: O'Neill, L. A. J. and Bowie, A. eds. Interleukin protocols., Vol. 60. Methods in Molecular Medicine Vol. 60. New Jersey: Humana Press, pp. 369-383., (10.1385/1-59259-146-9:369)
• Brennan, P. and Astoul, E. 2001. Applications of green fluorescent protein in cell signaling. In: O'Neill, L. A. J. and Bowie, A. eds. Interleukin Protocols., Vol. 60. Methods in Molecular Medicine Vol. 60. Totowa, New Jersey: Humana Press, pp. 385-391., (10.1385/1-59259-146-9:385)
• Brennan, P. 2001. Signalling events regulating lymphoid growth and survival. Seminars in Cancer Biology 11(6), pp. 415-421. (10.1006/scbi.2001.0408)
• Mehl, A. M., Floettmann, J. E., Jones, M., Brennan, P. and Rowe, M. 2001. Characterization of intercellular adhesion molecule-1 regulation by Epstein-Barr virus-encoded latent membrane protein-1 identifies pathways that cooperate with nuclear factor κB to activate transcription. Journal of Biological Chemistry 276(2), pp. 984-992. (10.1074/jbc.M003758200)
• Brennan, P., Floettman, J. E., Mehl, A., Jones, M. and Rowe, M. 2001. Mechanism of action of a novel latent membrane protein-1 dominant negative. Journal of Biological Chemistry 276(2), pp. 1195-1203. (10.1074/jbc.M005461200)

1999

• Brennan, P., Babbage, J. W., Thomas, G. and Cantrell, D. 1999. p70s6k integrates phosphatidylinositol 3-Kinase and rapamycin-regulated signals for E2F regulation in T lymphocytes. Molecular and Cellular Biology 19(7), pp. 4729-4738.
• Vanhaesebroeck, B. et al. 1999. Autophosphorylation of p110δ phosphoinositide 3‐kinase: a new paradigm for the regulation of lipid kinases in vitro and in vivo. The EMBO Journal 18(5), pp. 1292-1302. (10.1093/emboj/18.5.1292)

1998

• Arrieumerlou, C., Donnadieu, E., Brennan, P., Keryer, G., Bismuth, G., Cantrell, D. and Trautmann, A. 1998. Involvement of phosphoinositide 3-kinase and Rac in membrane ruffling induced by IL-2 in T cells. European Journal of Immunology 28(6), pp. 1877-1885. (10.1002/(SICI)1521-4141(199806)28:06<1877::AID-IMMU1877>3.0.CO;2-I)
• Brennan, P. and O'Neill, L. A. J. 1998. Inhibition of nuclear factor kB by direct modification in whole cells mechanism of action of nordihydroguaiaritic acid, curcumin and thiol modifiers. Biochemical Pharmacology 55(7), pp. 965-973. (10.1016/S0006-2952(97)00535-2)

1997

• Brennan, P., Babbage, J. W., Burgering, B. M. T., Groner, B., Reif, K. and Cantrell, D. A. 1997. Phosphatidylinositol 3-kinase couples the interleukin-2 receptor to the cell cycle regulator E2F. Immunity 7(5), pp. 679-689. (10.1016/S1074-7613(00)80388-X)

1996

• Brennan, P. and O'Neill, L. A. J. 1996. 2-Mercaptoethanol restores the ability of nuclear factor kB (NFkB) to bind DNA in nuclear extracts from interleukin 1-treated cells incubated with pyrollidine dithiocarbamate (PDTC). Biochemical Journal -London- 320, pp. 975-981.

1995

• Brennan, P. and O'Neill, L. A. 1995. Effects of oxidants and antioxidants on nuclear factor kappa B activation in three different cell lines: evidence against a universal hypothesis involving oxygen radicals. Acta Biochimica et Biophysica 1260(2), pp. 167-175. (10.1016/0167-4781(94)00186-7)